JOP20170133B1 - عوامل مضادة لمستقبل أنجيوتنسين-1 - Google Patents

عوامل مضادة لمستقبل أنجيوتنسين-1

Info

Publication number
JOP20170133B1
JOP20170133B1 JOJO/P/2017/0133A JOP20170133A JOP20170133B1 JO P20170133 B1 JOP20170133 B1 JO P20170133B1 JO P20170133 A JOP20170133 A JO P20170133A JO P20170133 B1 JOP20170133 B1 JO P20170133B1
Authority
JO
Jordan
Prior art keywords
angiotensin
receptor antagonists
compounds
formula
gestational
Prior art date
Application number
JOJO/P/2017/0133A
Other languages
English (en)
Inventor
Earl Cable Edward
Stalewski Jacek
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JOP20170133B1 publication Critical patent/JOP20170133B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بالكشف عن مركبات لها الصيغة (I) أو ملح مقبول صيدلانيا منها: AA1-Arg-Val-AA4-AA5-His-Pro-AA8-OH (I), حيث تم تحديد AA1 وAA4 وAA5 وAA8 في المواصفة. ويمكن استخدام مركبات الصيغة (I) لمعالجة ارتفاع ضغط الدم (على سبيل المثال ارتفاع ضغط الدم الناتج عن الحمل)، أو تسمم الحمل، أو مرض كلوي ناتج عن الحمل.
JOJO/P/2017/0133A 2016-06-02 2017-05-29 عوامل مضادة لمستقبل أنجيوتنسين-1 JOP20170133B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344831P 2016-06-02 2016-06-02
EP16185403 2016-08-23

Publications (1)

Publication Number Publication Date
JOP20170133B1 true JOP20170133B1 (ar) 2022-03-15

Family

ID=58992873

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2017/0133A JOP20170133B1 (ar) 2016-06-02 2017-05-29 عوامل مضادة لمستقبل أنجيوتنسين-1

Country Status (16)

Country Link
EP (1) EP3464324B1 (ar)
JP (1) JP7139251B2 (ar)
BR (1) BR112018074190A2 (ar)
CL (1) CL2018003324A1 (ar)
DK (1) DK3464324T3 (ar)
ES (1) ES2878153T3 (ar)
HU (1) HUE054334T2 (ar)
IL (1) IL262981B2 (ar)
JO (1) JOP20170133B1 (ar)
MX (1) MX2018014364A (ar)
MY (1) MY191062A (ar)
PH (1) PH12018502440A1 (ar)
PL (1) PL3464324T3 (ar)
SI (1) SI3464324T1 (ar)
UA (1) UA123367C2 (ar)
ZA (1) ZA201807767B (ar)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594302A (en) 2008-12-29 2013-07-26 Trevena Inc Beta-arrestin effectors and compositions and methods of use thereof

Also Published As

Publication number Publication date
IL262981B1 (en) 2023-09-01
SI3464324T1 (sl) 2021-08-31
DK3464324T3 (da) 2021-06-28
JP7139251B2 (ja) 2022-09-20
MY191062A (en) 2022-05-30
PH12018502440A1 (en) 2019-09-09
IL262981A (en) 2018-12-31
MX2018014364A (es) 2019-02-14
BR112018074190A2 (pt) 2019-03-26
ZA201807767B (en) 2023-04-26
EP3464324A1 (en) 2019-04-10
PL3464324T3 (pl) 2021-10-25
CL2018003324A1 (es) 2019-06-07
IL262981B2 (en) 2024-01-01
ES2878153T3 (es) 2021-11-18
UA123367C2 (uk) 2021-03-24
HUE054334T2 (hu) 2021-08-30
EP3464324B1 (en) 2021-04-07
JP2019520331A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
MX2018000542A (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
MX2019011911A (es) Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.
MY194319A (en) Aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201591420A1 (ru) Гетероарильные соединения и их применение
BR112016008541A2 (pt) composições úteis para tratar distúrbios relacionados a kit
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
CR20200290A (es) PÉPTIDOS Y COMPOSICIONES PARA EL TRATAMIENTO DE DAÑO ARTICULAR (Divisional 2015-0466)
EA201591665A1 (ru) Оральные составы деферазирокса
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
BR112017006420A2 (pt) derivados de ácido borônico
TW201612160A (en) Compounds as CRTH2 antagonist and uses thereof
BR112016014404A2 (pt) Composições e métodos para tratamento de glaucoma
SA518392179B1 (ar) مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها
NZ738990A (en) Cgrp receptor antagonists
CY1121624T1 (el) Παραγωγα 2-αρυλο-4-υδροξυ-1,3-θειαζολιου χρησιμα ως αναστολεις trpm8 για τη θεραπεια της νευραλγιας, του πονου, της χαπ και του ασθματος
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
LT3458039T (lt) Trijų komponentų derinys, susidedantis iš grynų 5-ht6 receptoriaus antagonistų, acetilcholinesterazės inhibitorių ir nmda receptoriaus antagonisto
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
MX387920B (es) Peptidos antagonistas de prgc.
GB2550734B (en) Overcoming the retardation of cement hydration from dispersing agents used in suspension of additives
WO2015164411A3 (en) Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides
LT3500306T (lt) Trigubas derinys iš histamino-3 receptoriaus atvirkštinių agonistų, acetilcholinesterazės inhibitorių ir nmda receptoriaus antagonisto